In:
Histopathology, Wiley, Vol. 71, No. 2 ( 2017-08), p. 305-315
Abstract:
Cancer/testis antigens ( CTA s) are detected in cancer cells but not in healthy normal tissues, with the exception of gametogenic tissues. CTA s are highly immunogenic proteins, and thus represent ideal targets for cytotoxic T‐lymphocyte‐mediated specific immune therapy. The aim of this study was to screen CTA expression in various types of salivary gland carcinoma and to clarify clinicopathological significance of MAGE ‐A and NY ‐ ESO ‐1 expression in adenoid cystic carcinomas (AdCCs) of the salivary gland, which is one of the most common salivary gland carcinomas, and usually has a fatal outcome. Methods and results We used immunohistochemistry to examine the expression of four CTA s ( MAGE ‐A, NY ‐ ESO ‐1, CT 7, and GAGE 7) in various types of salivary gland carcinoma ( n = 95). When carcinoma cases were divided into low‐grade and intermediate/high‐grade types, NY ‐ ESO ‐1 and CT 7 were expressed more frequently in intermediate/high‐grade carcinomas. We then focused on MAGE ‐A and NY ‐ ESO ‐1 expression in a large cohort of adenoid cystic carcinomas (Ad CC s) ( n = 46). MAGE ‐A and NY ‐ ESO ‐1 were frequently expressed in Ad CC ; specifically, MAGE ‐A was expressed in 〉 60% of the Ad CC cases. MAGE ‐A expression and tumour site (minor salivary gland) were identified as independent risk factors for locoregional tumour recurrence. Conclusions These findings suggest that CTA s may be expressed in a variety of salivary gland carcinomas, especially in those with higher histological grades. In addition, MAGE ‐A, which is frequently expressed in Ad CC cases, may be a useful prognostic factor for poorer locoregional recurrence‐free survival.
Type of Medium:
Online Resource
ISSN:
0309-0167
,
1365-2559
DOI:
10.1111/his.2017.71.issue-2
Language:
English
Publisher:
Wiley
Publication Date:
2017
detail.hit.zdb_id:
2006447-0
detail.hit.zdb_id:
131914-0
Permalink